Dermatitis News

Seborrheic dermatitis is more prevalent across the world than previously believed, with a global pooled prevalence of 4.38%, according to a comprehensive meta-analysis.

Enrollment has been completed in a phase 2 clinical trial for the evaluation of bempikibart as a treatment for adults with persistent, moderate to severe atopic dermatitis, Q32 Bio announced in a press release.

The FDA has approved Zoryve cream 0.15% for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged 6 years and older, Arcutis announced in a press release.

The FDA is working to finalize an action letter regarding Arcutis’ supplemental new drug application for roflumilast cream 0.15% indicated for atopic dermatitis, the company announced in a press release.

Dupilumab treatment was associated with the reduced risk for atopic march progression in pediatric and adolescent patients with atopic dermatitis, according to a study.

A picture-based scorecard with multiple skin tones facilitated the assessment of atopic dermatitis among infants, according to a study published in Annals of Allergy, Asthma & Immunology.

Healio has compiled June’s most-read news in dermatology.

Makeup not only has cosmetic applications, but medical ones too.

Vtama cream 1% has been approved in Japan for the treatment of adults with psoriasis as well as patients aged 12 years and older with atopic dermatitis, Dermavant Sciences announced in a press release.

Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.